Avidity Biosciences Inc
NASDAQ:RNA

Watchlist Manager
Avidity Biosciences Inc Logo
Avidity Biosciences Inc
NASDAQ:RNA
Watchlist
Price: 30.81 USD 0.62% Market Closed
Market Cap: 3.7B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

RNA Price Targets Summary
Avidity Biosciences Inc

Wall Street analysts forecast RNA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RNA is 68.18 USD with a low forecast of 48.48 USD and a high forecast of 100.8 USD.

RNA Lowest Forecast
Wall Street Target
48.48 USD
57% Upside
RNA Average Forecast
Wall Street Target
68.18 USD
121% Upside
RNA Highest Forecast
Wall Street Target
100.8 USD
227% Upside
Lowest
Price Target
48.48 USD
57% Upside
Average
Price Target
68.18 USD
121% Upside
Highest
Price Target
100.8 USD
227% Upside
Avidity Biosciences Inc Competitors:
Price Targets
EXAS
Exact Sciences Corp
25% Upside
CUV
Clinuvel Pharmaceuticals Ltd
151% Upside
UTHR
United Therapeutics Corp
29% Upside
L
LYTIX
Lytix Biopharma AS
79% Upside
EXAS
Exact Sciences Corp
25% Upside
CUV
Clinuvel Pharmaceuticals Ltd
151% Upside
UTHR
United Therapeutics Corp
29% Upside
L
LYTIX
Lytix Biopharma AS
79% Upside
PRQR
ProQR Therapeutics NV
519% Upside
TRDA
Entrada Therapeutics Inc
226% Upside
F
FLUO
Fluoguide AS
158% Upside
2616
CStone Pharmaceuticals
24% Downside

Revenue
Forecast

Revenue Estimate
Avidity Biosciences Inc

For the last 5 years the compound annual growth rate for Avidity Biosciences Inc's revenue is 36%. The projected CAGR for the next 3 years is 205%.

36%
Past Growth
205%
Estimated Growth
Estimates Accuracy
5%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Avidity Biosciences Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
4%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Avidity Biosciences Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-57%
Average Miss
What are analyst estimates?

See Also

Summary
RNA intrinsic value, competitors valuation, and company profile.
DCF Valuation
RNA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
RNA stock valuation using valuation multiples.
Wall Street Estimates
RNA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
RNA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is RNA's stock price target?
Price Target
68.18 USD

According to Wall Street analysts, the average 1-year price target for RNA is 68.18 USD with a low forecast of 48.48 USD and a high forecast of 100.8 USD.

What is Avidity Biosciences Inc's Revenue forecast?
Projected CAGR
205%

For the last 5 years the compound annual growth rate for Avidity Biosciences Inc's revenue is 36%. The projected CAGR for the next 3 years is 205%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 256,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.